

Anti-CD6 Antibody (Itolizumab)

Introduction

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) that targets the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T cell proliferation and inhibits the production of pro-inflammatory cytokines such as INF- γ , TNF α , and IL-6. Itolizumab can be used in the study of psoriasis, rheumatoid arthritis (RA), and COVID-19.

Product parameters

Alternative Names	ALZUMAb, T1h, EQ001
Target Accession	P30203
Target	CD6
CAS number	1116433-11-4
Molecular Weight	146.66 kDa
Host	CHO
Reactivity	Human, Mouse, Rat
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

